• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience

    10/23/25 11:55:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRK alert in real time by email

    BOSTON, Oct. 23, 2025 /PRNewswire/ -- eschbach is pleased to share that Merck (NYSE:MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enhancing its ability to deliver real-time, actionable insights across global operations.

    eschbach (PRNewsfoto/eschbach)

    This implementation supports Merck's continued drive for greater transparency, responsiveness, and efficiency throughout its supply chain. With Shiftconnector now serving as its foundational layer, Merck is advancing this capability even further—standardizing KPIs, enhancing cross-departmental communication, and embedding analytics directly into their 24/7 operations at all seven of its tier management levels.

    "Our Visual Factory, powered by Shiftconnector, is transforming the way we operate," said Besufekad "Besu" Alemayehu, Senior Vice President, Digital Manufacturing for Merck. "It gives our teams a real-time, unified view of plant performance, enabling faster, smarter decisions. By combining our operational expertise with Shiftconnector's intelligent platform, we're building a more agile, transparent, and resilient supply chain that helps us deliver life-saving medicines more efficiently."

    In under five months, Merck and eschbach successfully deployed Shiftconnector to more than 9,000 users across multiple global sites and all above site functions. Now serving as a core component of Merck's Visual Factory, Shiftconnector provides a single source of truth for operational data and streamlines essential processes such as shift handovers, equipment tracking, and deviation reporting. Its AI-driven features will give teams fast access to historical insights and institutional knowledge—critical in an industry navigating workforce transitions. This foundation ensures the right information reaches the right person at the right time, enabling seamless collaboration throughout Merck's tiered management system.

    "We're proud to help power Merck's Visual Factory transformation," said Andreas Eschbach, CEO of eschbach. "Together, we're creating a smarter, more resilient manufacturing environment—one where people are empowered by real-time data and AI-driven insights to make better decisions, faster."

    This milestone reflects Merck's continued investment in its digital transformation journey, reinforcing its commitment to innovation, quality, and delivering life-saving medicines with greater speed and reliability.

    About eschbach

    With its global headquarters in Southern Germany and its North America headquarters in Boston, MA, eschbach is the premier enterprise software developer for pharmaceutical manufacturing daily management systems and more. Shiftconnector incorporates AI technology and helps manufacturing teams take charge of facility operations, process safety, asset performance, and production quality. eschbach serves the pharmaceutical industry and other process industries, transforming digital manufacturing operations that helps managers, operators, and technicians to achieve the highest level of team communications. The award-winning solution is trusted worldwide by leading manufacturing companies such as Merck, Roche, and Bayer. For more information, visit www.eschbach.com.

    Media Contact

    Dawn Fontaine

    Ripple Effect Communications

    T: 617-536-8887

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/eschbachs-shiftconnector-helps-power-mercks-visual-factory-to-drive-greater-transparency-agility-and-supply-chain-resilience-302593033.html

    SOURCE eschbach

    Get the next $MRK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRK

    DatePrice TargetRatingAnalyst
    10/13/2025$95.00Neutral
    Citigroup
    9/17/2025$90.00Buy → Hold
    Berenberg
    5/14/2025$84.00Buy → Neutral
    Citigroup
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    2/18/2025$128.00 → $105.00Buy → Hold
    Deutsche Bank
    2/10/2025$121.00 → $100.00Buy → Hold
    TD Cowen
    1/8/2025$110.00Buy → Hold
    Truist
    12/20/2024$136.00 → $105.00Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Seidman Christine E

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    10/2/25 9:31:14 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Glocer Thomas H

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    10/2/25 9:29:34 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Coe Mary Ellen

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    10/2/25 9:28:01 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience

    BOSTON, Oct. 23, 2025 /PRNewswire/ -- eschbach is pleased to share that Merck (NYSE:MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enhancing its ability to deliver real-time, actionable insights across global operations. This implementation supports Merck's continued drive for greater transparency, responsiveness, and efficiency throughout its supply chain. With Shiftconnector now serving as its found

    10/23/25 11:55:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025

    Results from the Phase 3 CORALreef Lipids and HeFH trials of investigational oral PCSK9 inhibitor enlicitide decanoate will be presented for the first time Presentations across hypercholesterolemia and pulmonary arterial hypertension (PAH) underscore Merck's continued commitment to research with the goal of helping address the cardiovascular (CV) epidemic and significant burden of cardio-pulmonary diseases on public health Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company's cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, La., from

    10/23/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer

    Applications based on Phase 3 KEYNOTE-905 results showing the combination improved event-free survival by 60%, reduced the risk of death by 50% and increased pathologic complete response rates by 48% compared with surgery alone If approved, these would be the first and only perioperative regimens to have improved survival in this patient population Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination wi

    10/23/25 6:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    SEC Filings

    View All

    Merck & Company Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Merck & Co., Inc. (0000310158) (Filer)

    9/9/25 4:33:09 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Merck & Company Inc.

    424B5 - Merck & Co., Inc. (0000310158) (Filer)

    9/4/25 4:15:44 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Merck & Company Inc.

    424B5 - Merck & Co., Inc. (0000310158) (Filer)

    9/2/25 8:15:19 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Merck with a new price target

    Citigroup resumed coverage of Merck with a rating of Neutral and set a new price target of $95.00

    10/13/25 8:54:29 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck downgraded by Berenberg with a new price target

    Berenberg downgraded Merck from Buy to Hold and set a new price target of $90.00

    9/17/25 7:56:07 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck downgraded by Citigroup with a new price target

    Citigroup downgraded Merck from Buy to Neutral and set a new price target of $84.00

    5/14/25 8:57:17 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Financials

    Live finance-specific insights

    View All

    Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

    10/1/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

    Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the Impact of Foreign Exchange KEYTRUDA Sales Were $8.0 Billion, Growth of 9% Both Nominally and Excluding the Impact of Foreign Exchange WINREVAIR Sales Were $336 Million Animal Health Sales Were $1.6 Billion, Growth of 11% Both Nominally and Excluding the Impact of Foreign Exchange GARDASIL/GARDASIL 9 Sales Were $1.1 Billion, a Decline of 55% Both Nominally and Excluding the Impact of Foreign Exchange GAAP EPS Was $1.76; Non-GAAP EPS Was $2.13; GAAP and Non-GAAP EPS Include a Charge of $0.07 per Share for Closing of Hengrui Pharma License Agreement Announce

    7/29/25 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Announces Fourth-Quarter 2025 Dividend

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

    7/22/25 11:53:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

    WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua

    11/14/23 5:25:00 PM ET
    $ASH
    $MRK
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/13/24 4:55:49 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/9/23 10:54:48 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/9/22 3:15:54 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care